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OBJECTIVE — To compare cardiovascular disease (CVD) risk factors among recently diag-
nosed youth with type 2 diabetes and nondiabetic youth and investigate whether demographic,
behavioral, or metabolic factors might account for observed differences.
RESEARCH DESIGN AND METHODS — Data from 106 type 2 diabetic and 189
nondiabeticmultiethnicyouth,aged10–22years,wereanalyzed.PrevalenceofCVDriskfactors
were age and race/ethnicity adjusted using direct standardization. Multiple linear regression
models were sequentially adjusted for demographic, behavioral (dietary saturated fat intake and
physical activity), and metabolic (body adiposity and glycemia) factors to explore possible
mechanismsassociatedwithdifferencesinCVDriskfactorsbetweenthecaseandcontrolgroups.
RESULTS — Compared with control subjects, youth with type 2 diabetes had a higher prev-
alence of elevated blood pressure, obesity, large waist circumference, low HDL cholesterol, high
triglycerides,andhighalbumin-to-creatinineratio(P0.05foreachriskfactor).Type2diabetic
youth also had higher levels of apolipoprotein B, ﬁbrinogen, interleukin (IL)-6, C-reactive
protein, and leptin; lower adiponectin levels; and denser LDL particles (P  0.05 for each risk
factor). Adjustment for BMI, waist circumference, and A1C substantially attenuated differences
in the CVD risk factors between the case/control groups, except for ﬁbrinogen and IL-6, which
remained signiﬁcantly higher in type 2 diabetic youth.
CONCLUSIONS — Compared with control youth, type 2 diabetic youth have a less favor-
able CVD risk factor proﬁle. Adiposity and glycemia are important contributors to differences in
CVD risk proﬁles among type 2 diabetic and control youth. Inﬂammatory and prothrombotic
factors may also play an important role.
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T
here has been a dramatic increase in
the prevalence of type 2 diabetes in
children and adolescents during the
past two decades (1). Much of the health
burden of type 2 diabetes in youth will
result from chronic complications, in-
cludingcardiovasculardisease(CVD)(2).
In adults with type 2 diabetes, CVD oc-
curs earlier and is associated with higher
mortalitycomparedwiththegeneralpop-
ulation (3). Early adult-onset type 2 dia-
betes (diagnosed age 18–44 years) has
been associated with more aggressive
CVD than later-onset type 2 diabetes (4),
suggesting that CVD complications re-
sulting from type 2 diabetes diagnosed in
youth may be even more unfavorable.
Obesity, dyslipidemia, hypertension,
and smoking have long been recognized as
major risk factors for cardiovascular mor-
bidity and mortality in adults. The typical
lipid abnormalities in type 2 diabetic adults
are low levels of HDL cholesterol and high
levels of triglycerides (5). Studies have re-
cently identiﬁed novel lipid abnormalities,
including a preponderance of small, dense
LDL particles and high levels of apolipo-
protein B (apoB) (6). Other novel CVD
risk factors indicate systemic inﬂamma-
tion, a prothrombotic state, and endothe-
lial dysfunction, marked by altered levels
of interleukin (IL)-6, C-reactive protein
(CRP), ﬁbrinogen, adipocytokines, and
microalbuminuria.
Given the recent emergence of type 2
diabetes in adolescent populations, the
relationship between type 2 diabetes and
CVD risk factors among youth has not
been well characterized. Although type 2
diabetes itself is considered a risk factor
for CVD, we hypothesized that youth
with recently diagnosed type 2 diabetes
would have a less favorable CVD risk fac-
tor proﬁle, excluding diabetes status,
compared with nondiabetic youth. We
also explored whether measures of adi-
posity(BMIandwaistcircumference),hy-
perglycemia, and behavioral factors
(physicalactivityanddietaryintakeofsat-
urated fat) may account for observed dif-
ferences in CVD risk factors between type
2 diabetic and nondiabetic youth.
RESEARCH DESIGN AND
METHODS— The study population
included participants in the SEARCH
Case-Control (SEARCH-CC) study, an
ancillary study to the multicenter
SEARCH for Diabetes in Youth study (7).
SEARCH study participants who were
residents of Colorado or South Carolina,
aged 10–22 years, and African American,
Hispanic, or non-Hispanic whites were
invited to participate in the SEARCH-CC
study. Because of recruitment from the
larger SEARCH study, which had ascer-
tained case subjects diagnosed through
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jects had aged to 22 years at the time of
recruitment into the SEARCH-CC study.
Case subjects were identiﬁed using net-
works of health care providers. Type 2
diabetes was deﬁned by provider diagno-
sis. In our population, provider classiﬁca-
tionofdiabetestypewaspreviouslyfound
tobeconsistentwiththeexpectedclinical
and biochemical characteristics, includ-
ing low frequency of insulin treatment,
absence of autoimmune markers, and
presence of markers of insulin resistance
among youth with type 2 diabetes (8).
Overall, 52% of the eligible SEARCH
study youth with type 2 diabetes partici-
pated in the SEARCH-CC study. Nondia-
betic control youth, aged 10–22 years
and self-identiﬁed as African American,
Hispanic,ornon-Hispanicwhite,werere-
cruited from primary care ofﬁces in the
same geographic areas. Nondiabetic sta-
tus in the control subjects was conﬁrmed
by fasting glucose values. Primary care
practices were chosen as the sampling
frame for control subjects in order to
closely represent the underlying popula-
tion that gave rise to the type 2 diabetic
casesubjects.Additionaldetailsregarding
sampling and recruitment for the
SEARCH-CC study have been published
(9). Written informed consent was ob-
tained from participants aged 18 years,
and assent was obtained for participants
aged 18 years.
Outcome measures
Blood was drawn after an overnight fast
for measurement of total cholesterol, trig-
lycerides, HDL cholesterol, apoB, li-
poprotein cholesterol distribution, and
calculation of the LDL relative ﬂotation
rate (Rf), ﬁbrinogen, IL-6, CRP, leptin,
and adiponectin. A morning spot-urine
sample was collected for measurement of
urinary albumin and creatinine for calcu-
lation of the albumin-to-creatinine ratio
(ACR) (micrograms of albumin per milli-
gram of creatinine). Specimens were pro-
cessed and shipped within 24 h to the
Northwest Lipid Metabolism and Diabe-
tes Research Laboratories for analyses.
Measurementsofplasmacholesterol,trig-
lycerides, and HDL cholesterol were per-
formed enzymatically on a Hitachi 917
autoanalyzer. LDL cholesterol was calcu-
lated by the Friedewald equation for tri-
glyceride concentrations 400 mg/dl
(4.52 mmol/l/l) and by the BetaQuantiﬁ-
cation procedure for triglycerides 400
mg/dl (10). ApoB was measured by a cal-
ibrated nephelometric system. The li-
poprotein cholesterol distribution used a
modiﬁcation of a previously described
technique (11). Urinary albumin was
measured by nephelometry, and urinary
creatinine was measured by the Jaffe
method using a Roche Diagnostics re-
agent on the Hitachi 917 autoanalyzer.
Serum IL-6 concentrations were deter-
mined by a capture sandwich immunoas-
say using a Bio-Plex suspension array
system and commercially available re-
agents from Linco Research. High-
sensitivity CRP and ﬁbrinogen were
assayed by a Dade Behring nepholometer
using Behring reagents.
Threesittingbloodpressuremeasure-
ments were obtained and averaged. Cur-
rent smoking status was obtained from
self-report. Height was measured to the
nearest 0.1 cm by stadiometer. Weight
was measured to the nearest 0.1 kg using
an electronic scale. Waist circumference
was measured to the nearest 0.1 cm using
the National Health and Nutrition Exam-
ination Survey protocol (12). Anthropo-
metric measurements were taken twice
and averaged. Height and weight mea-
surements were used to calculate BMI
(kg/m
2).
Categorical CVD risk factors were de-
ﬁned as elevated blood pressure (systolic
or diastolic blood pressure 95th per-
centile for age, sex, and height or use of
antihypertension medication), obesity
(BMI 95th percentile for age and sex),
largewaistcircumference(90thpercen-
tile for age and sex), high LDL cholesterol
(130 mg/dl), low HDL cholesterol
(35 mg/dl), high triglycerides (150
mg/dl), current smoking, and elevated
urinary ACR (30 g/mg) (13,14).
Covariates
Race/ethnicity was obtained from self-
report using 2000 Census–based ques-
tions (15). Fasting A1C was measured by
an ion exchange high-performance liquid
chromatography instrument. Dietary in-
takewasascertainedusingamodiﬁedver-
sion of the Kids Food Questionnaire (16).
Saturated fat intake was calculated as
grams per 1,000 kcal. Physical activity
was obtained by self-report using ques-
tions based on the Youth Risk Behavior
Surveillance System (17) and was catego-
rized as the average number of 30-min
blocks of moderate-to-vigorous activity
per day. Self-reported Tanner staging was
used to categorize pubertal development
using scales ranging from 1 (prepubertal)
to 5 (adult).
Statistical analysis
Statistical analyses were performed using
PC-SAS (version 9.1). Two sets of analy-
ses were performed. In the ﬁrst analysis,
eightCVDriskfactorswerecategorizedto
compare risk factor prevalence between
type 2 diabetic and nondiabetic youth.
TheBreslow-Daytestwasusedtoevaluate
interactions between race/ethnicity and
age-group categories (10–15 vs. 16–22
years) and diabetes status. None of the
interactions were signiﬁcant (all P values
0.05); thus, all race/ethnicity and age-
groups were included together in the
Table 1—Demographic, metabolic, and behavioral characteristics of the study participants
Characteristic Type 2 diabetes Control subjects P
n 106 189
Female n (%) 73 (69) 113 (60) 0.12
Race/ethnicity n (%)
African American 58 (55) 54 (29)
Hispanic 18 (17) 32 (17) 0.0001
Non-Hispanic white 30 (28) 103 (54)
Age (years) 15.7 (4.4) 14.3 (4.6) 0.0001
Age at diagnosis (years) 13.7 (4.0) — —
Duration of diabetes (years) 1.5 (1.4) — —
A1C (%) 7.4 (2.6) 5.2 (0.4) 0.0001
BMI (kg/m
2) 35.0 (8.7) 23.7 (7.1) 0.0001
Waist circumference (cm)
Female 108.3 (22.1) 80.4 (16.4) 0.0001
Male 110.2 (13.9) 77.2 (20.3) 0.0001
Saturated fat (g)/1,000 kcal 14.8 (4.3) 13.9 (3.6) 0.005
Physical activity* 4.8 (6.3) 5.6 (6.3) 0.17
Data are means (interquartile range), unless otherwise noted. *Number of 30-min blocks of moderate-to-
vigorous physical activity per day.
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risk factors were age and race/ethnicity
adjusted using direct standardization.
Differences in adjusted prevalence be-
tween the case/control groups were eval-
uated using 
2 tests.
In a second set of analyses, multiple
linear regression models were used to ex-
plore differences in CVD risk factors
(modeled as continuous variables) be-
tween case and control youth. All models
were adjusted for demographic factors
(age, sex, and race/ethnicity) and then se-
quentially adjusted for behavioral factors
(dietary saturated fat intake and physical
activity), adiposity (BMI and waist cir-
cumference), and glycemic control
(A1C). A ﬁnal, fully adjusted model in-
cluded all covariates signiﬁcantly associ-
ated with any CVD risk factor.
Comparison of these models allowed in-
vestigation of possible mechanisms that
may account for differences in speciﬁc
CVD risk factors between type 2 diabetic
and control youth. Nonnormally distrib-
uted variables (triglycerides, apoB, IL-6,
and CRP) were log transformed for statis-
tical testing, and differences in geometric
means are reported to present these vari-
ablesintheiroriginalscale.Estimateddif-
ferences were positive when values for
diabetic youth were greater than for con-
trol youth. In separate models for each
CVDriskfactor,waistcircumferenceonly
or BMI only were entered into the models
instead of both measures to investigate if
the distribution of body fat, rather than
overall adiposity, might differentially ac-
count for discrepant levels among dia-
betic and control youth.
RESULTS— The analyses included
data from type 2 diabetic (n  106) and
nondiabetic (n  189) youth, with data
on CVD risk factors and covariates. Only
diabetic case (n  95) and control (n 
174) subjects with complete data on all
eight categorized CVD risk factors were
used in the analysis comparing CVD risk
factor prevalence between the case and
control groups. Demographic, metabolic,
and behavioral characteristics of the dia-
betic and control participants are shown
inTable1.Comparedwithcontrolyouth,
diabetic youth were slightly older, more
likely to be African American, had higher
mean BMI and A1C, and had a greater
intake of saturated fat per 1,000 kcal. Ta-
ble 2 shows that youth with diabetes had
higher age- and race/ethnicity-adjusted
prevalence of elevated blood pressure,
obesity, large waist circumference, low
HDL cholesterol, high triglycerides, and
high ACR. There was little difference be-
tween diabetic and control youth in the
adjusted prevalence of high LDL choles-
terol or current smoking.
Figure 1 shows that of eight categor-
ical CVD risk factors the overall distribu-
tion of the total number of CVD risk
factors (0, 1, 2, 3, or 4) in youth was
signiﬁcantly different (P  0.0001), with
a less favorable CVD risk proﬁle for dia-
betic youth. A total of 60.0% of diabetic
youthhadthreeormoreCVDriskfactors,
compared with 13.1% of nondiabetic
control youth. Diabetic youth had an av-
erage of 2.9 risk factors compared with
1.0 among control youth (P  0.0001).
Table 3 shows the adjusted means
and mean differences for each CVD risk
factor for diabetic and nondiabetic youth.
In model 1, adjusted only for demo-
graphic variables, diabetic youth had
higher levels of triglycerides, systolic
blood pressure, apoB, ﬁbrinogen, IL-6,
CRP,andleptin;lowerlevelsofHDLcho-
lesterol and adiponectin; and greater LDL
particle density compared with nondia-
beticyouth.Therewerenosigniﬁcantdif-
ferences in mean LDL cholesterol
betweenthegroups(datanotshown).Ad-
justmentforBMIandwaistcircumference
(model2)substantiallyattenuatedthedif-
ferences in HDL cholesterol, systolic
bloodpressure,CRP,andadiponectinbe-
tween the two groups. This adjustment
for adiposity reversed the direction of the
difference in leptin levels between the
groupssuchthatcontrolyouthhada38%
higher average leptin level than diabetic
youth. In model 3, adjustment for A1C
signiﬁcantly attenuated the differences
between case and control subjects in
apoB, LDL Rf, and CRP levels. There was
also a substantial lessening of the differ-
ences in triglyceride levels (a 58% reduc-
tion) with adjustment for A1C.
Adjustment for behavioral factors did not
signiﬁcantly inﬂuence the mean differ-
ences between diabetic and nondiabetic
youthforanyoftheCVDriskfactors(data
not shown). In model 4, adjustment for
all of the demographic and metabolic fac-
tors (age, sex, race/ethnicity, BMI, waist
circumference, and A1C) resulted in a
Figure1—DistributionofeightCVDriskfactorsinyouthwithandwithouttype2diabetes.*P
0.0001.Riskfactorsincludeelevatedbloodpressure,obesity,largewaistcircumference,lowHDL
cholesterol, high triglycerides, high LDL cholesterol, high ACR, and current smoking.
Table2—PrevalenceofCVDriskfactorsintype2diabeticandnondiabeticyouth,adjustedfor
age and race/ethnicity
CVD risk factor
Prevalence*
P
Type 2 diabetic subjects
(n  95)
Control subjects
(n  174)
Elevated blood pressure 27 (18–36) 5 (2–8) 0.0001
Obesity 86 (79–93) 26 (19–33) 0.0001
Large waist circumference 82 (74–90) 22 (16–28) 0.0001
Low HDL cholesterol 25 (16–34) 5 (2–8) 0.0001
High triglycerides 27 (18–36) 6 (2–10) 0.0001
High ACR 17 (9–25) 7 (3–11) 0.02
High LDL cholesterol 14 (7–21) 10 (6–14) 0.29
Current smoking 5 (1–9) 7 (3–11) 0.56
Dataare%(95%CI).*OnlyparticipantswithcompletedataontheseeightCVDriskfactorswereusedinthis
analysis.
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ences between case and control youth in
most of the CVD risk factors, with the
notable exceptions of higher ﬁbrinogen
and IL-6 levels in diabetic youth and
higher CRP levels in nondiabetic youth.
In the fully adjusted models, the levels of
ﬁbrinogen and IL-6 were 22 and 116%
higher, respectively, and CRP levels were
Table 3—Means and mean differences of CVD risk factors for type 2 diabetic and nondiabetic control youth, adjusted for demographic and
metabolic characteristics
CVD risk factor Type 2 diabetic subjects Control subjects Mean difference* P
HDL cholesterol (mg/dl)
Model 1 42 (39–45) 50 (47–53) 8 0.0001
Model 2 47 (44–50) 48 (45–50) 1 0.5
Model 3 42 (38–45) 50 (47–53) 8 0.0001
Model 4 46 (43–50) 48 (46–51) 2 0.4
Triglycerides (mg/dl)†
Model 1 114 (98–133) 74 (65–84) 40 0.0001
Model 2 102 (86–122) 78 (68–89) 24 0.01
Model 3 95 (80–112) 78 (68–88) 17 0.04
Model 4 86 (71–104) 81 (71–92) 5 0.6
Systolic blood pressure (mmHg)
Model 1 115 (111–118) 107 (104–110) 8 0.0001
Model 2 110 (106–113) 109 (106–112) 1 0.7
Model 3 114 (110–117) 107 (104–110) 7 0.002
Model 4 109 (105–113) 109 (106–112) 0 0.9
ApoB (mg/dl)†
Model 1 83 (76–92) 60 (55–65) 23 0.0001
Model 2 76 (68–85) 61 (57–66) 15 0.001
Model 3 69 (62–77) 63 (58–68) 6 0.1
Model 4 65 (57–73) 64 (60–69) 1 0.9
LDL particle density (Rf)
Model 1 0.262 (0.255–0.268) 0.284 (0.278–0.262) 0.022 0.0001
Model 2 0.266 (0.259–0.274) 0.282 (0.276–0.288) 0.016 0.001
Model 3 0.274 (0.266–0.281) 0.280 (0.275–0.286) 0.007 0.1
Model 4 0.277 (0.269–0.285) 0.279 (0.274–0.285) 0.002 0.6
Fibrinogen (mg/dl)
Model 1 442 (420–465) 310 (292–328) 132 0.0001
Model 2 410 (387–433) 319 (303–336) 91 0.0001
Model 3 428 (400–455) 314 (295–332) 114 0.0001
Model 4 395 (369–422) 323 (306–340) 72 0.0001
IL-6 (pg/dl)
†
Model 1 7.9 (5.2–11.1) 2.9 (2.0–4.0) 5.0 0.0001
Model 2 6.8 (4.2–11.0) 3.0 (2.1–4.2) 3.8 0.005
Model 3 7.3 (4.3–12.3) 2.9 (2.1–4.1) 4.4 0.004
Model 4 6.5 (3.7–11.4) 3.0 (2.1–4.3) 3.5 0.03
CRP (mg/dl)†
Model 1 0.20 (0.12–0.33) 0.07 (0.04–0.10) 0.13 0.0004
Model 2 0.07 (0.04–0.12) 0.09 (0.06–0.13) 0.02 0.5
Model 3 0.12 (0.06–0.22) 0.08 (0.05–0.12) 0.04 0.2
Model 4 0.05 (0.03–0.08) 0.10 (0.07–0.14) 0.05 0.03
Leptin (ng/dl)
Model 1 24 (20–29) 15 (11–18) 9 0.0004
Model 2 13 (9–17) 18 (15–20) 5 0.03
Model 3 26 (20–32) 14 (10–18) 12 0.0009
Model 4 15 (10–19) 17 (15–20) 2 0.3
Adiponectin (g/dl)
Model 1 10.7 (9.0–12.3) 14.0 (12.6–15.3) 3.3 0.0008
Model 2 12.4 (10.6–14.3) 13.5 (12.1–14.8) 1.0 0.3
Model 3 10.8 (8.7–12.9) 13.9 (12.5–15.3) 3.1 0.01
Model 4 12.4 (10.3–14.6) 13.5 (12.1–14.8) 1.0 0.4
Dataaremeans(95%CI).Model1:adjustedforage,sex,andrace/ethnicity.Model2:model1plusBMIpluswaistcircumference.Model3:model1plusA1C.Model
4: model 1 plus BMI, waist circumference, and A1C. *Estimated differences are positive when values for diabetic youth are more than control youth. †Geometric
means are reported.
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with control subjects.
Models evaluating waist circumfer-
ence and BMI separately revealed similar
resultstomodelsincludingbothwaistcir-
cumference and BMI, with the exception
that waist circumference alone did not
signiﬁcantly attenuate the differences in
leptin levels between the case/control
subjects(datanotshown).IncludingTan-
ner stage in the regression models in ad-
dition to age had minimal effect on the
case/control subject difference in any
CVD risk factor levels.
CONCLUSIONS — We found that
youthwithtype2diabetesandarelatively
short diabetes duration (average 1.5
years) have a higher prevalence of many
CVD risk factors, including obesity and
central fat deposition, elevated blood
pressure, dyslipidemia, and elevated
ACR, compared with nondiabetic youth
of similar age, sex, and race/ethnicity.
Moreover, youth with diabetes tend to
have a cluster of multiple CVD risk fac-
tors, on average 2.9 vs. 1.0 in the control
group. Data from the Bogalusa Heart
Study (18) showed that the risk of ﬁbrous
plaques in the coronary arteries in youth
with three or four CVD risk factors was
three to eight times higher than the risk
with zero, one, or two risk factors.
Our data show that youth with type 2
diabetes have an atherogenic dyslipide-
mia characteristic of adults with type 2
diabetes, including low HDL cholesterol,
high triglycerides, and apoB and in-
creased levels of LDL particle density.
There were no signiﬁcant differences in
LDLcholesterolbetweencaseandcontrol
youth in our study. Elevated levels of
apoB in the presence of normal LDL cho-
lesterol levels have been associated with
acute myocardial infarction in adults
(19). Elevated apoB levels in the presence
of normal LDL cholesterol levels may be
explained by the increased concentration
of triglyceride-rich apoB-containing li-
poproteins and by the presence of dense
LDLthatisenrichedinapoBrelativetoits
cholesterol content. The association be-
tweentype2diabetesandhypertensionis
well established in adults, and our ﬁnd-
ings support a similar relationship in
youth.
Our ﬁndings suggest that adiposity
andglycemiccontrolaccountformuchof
the association between type 2 diabetes
and an unfavorable CVD risk factor pro-
ﬁle in youth. Excess adiposity, particu-
larly visceral abdominal obesity, is a well-
known risk factor for a cluster of
metabolic abnormalities, including insu-
lin resistance, dyslipidemia, and hyper-
tension, and is in turn associated with the
development of CVD. Consistent with
data in adults (20), we found that adipos-
ity, as measured by BMI and waist cir-
cumference, has a strong effect on
differences in HDL cholesterol, triglycer-
ides, and blood pressure levels between
diabetic and nondiabetic youth.
Accumulating evidence indicates that
adipose tissue releases a number of bioac-
tive mediators that play an important role
in the regulation of metabolic, inﬂamma-
tory, and thrombolytic pathways that are
associated with CVD risk (21). Most of
thesefactors,includingleptin,ﬁbrinogen,
IL-6, and CRP, are overproduced with
obesity. Conversely, plasma levels of adi-
ponectin, an insulin-sensitizing cytokine,
are downregulated during obesity. We
observed signiﬁcantly higher levels of
CRP, IL-6, ﬁbrinogen, and leptin and
lower levels of adiponectin in diabetic
youth than in healthy control subjects.
Consistentwithakeyroleofobesityinthe
dysregulation of these adipocytokines
and inﬂammatory factors in youth with
type 2 diabetes, case-control differences
disappeared (for adiponectin and leptin)
or were even reversed (for CRP) on ad-
justment for adiposity. Nevertheless, ﬁ-
brinogen and IL-6 remained signiﬁcantly
elevated in diabetic youth relative to non-
diabetic youth, independent of demo-
graphic factors, adiposity, and glycemia,
suggesting potential independent effects
ofﬁbrinogenandIL-6ontype2diabetes–
related CVD risk in youth.
Although obesity is a major contribu-
tor to cardiometabolic risk, prospective
studiessuggestapossibleindependentef-
fect of hyperglycemia (22). Hyperglyce-
miaacceleratestheformationofadvanced
glycationendproducts,whichcanleadto
atherogenic endothelial damage. Our re-
sults suggest smaller effects of hypergly-
cemia, relative to adiposity, on CVD risk
proﬁles in youth with diabetes. However,
the present data suggest that hyperglyce-
mia may have important effects on li-
poprotein risk factors, including apoB
and LDL particle size. Previous data from
the SEARCH study indicated that both
apoB levels and LDL density increased
signiﬁcantlywithincreasingA1Cinyouth
with either type 1 or type 2 diabetes (23).
Also,insulintherapyinadultswithtype2
diabetes was shown to signiﬁcantly re-
duce apoB levels (24).
This study has several limitations.
The cross-sectional data limits our ability
to deﬁnitively identify which factors and
pathways account for the unfavorable
CVD risk proﬁle observed in diabetic
youth compared with nondiabetic youth.
Also, the case-control design has an in-
herent limitation of potential selection
bias; however, comparisons between eli-
gibletype2diabeticcasesubjectsthatdid
and did not participate in this study re-
vealed no signiﬁcant differences in diabe-
tes duration, BMI z-scores, or waist
circumference (P  0.05 for each com-
parison). Additionally, there is a lack of
consensus regarding speciﬁc criteria and
cutoff values for CVD risk factors, partic-
ularly in youth. Despite this limitation,
our ﬁndings that the mean values and
prevalence for a majority of CVD risk fac-
tors are signiﬁcantly higher in type 2 dia-
betic youth is an important and timely
observationaboutthepotentialburdenof
comorbidities in this population, espe-
cially given that many CVD risk factors
encountered in youth track from child-
hood into adulthood (25).
In summary, when compared with
youth without diabetes, type 2 diabetic
youth have a higher prevalence of many
and multiple CVD risk factors. Adiposity
and glycemia are both independent and
interdependent contributors to a less fa-
vorable CVD risk proﬁle for diabetic
youth. Inﬂammatory and coagulation/
prothrombotic factors may also play an
important role. Because an earlier age of
onset of type 2 diabetes will likely in-
creasethelifetimeincidenceofCVDcom-
plications,earlypreventionandtreatment
strategies aimed at reducing the preva-
lence of CVD risk factors in these youth
are needed.
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